FDA Submission Update for ALTACE (Ramipril) by King Pharmaceuticals
King Pharmaceuticals has submitted a supplemental application for ALTACE (Ramipril) with a standard review priority.
Asset / Drug
Drug and asset intelligence for ALTACE (Ramipril) with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
ACE Inhibitor
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.